Four Versus Six Cycles Of Docetaxel And Cyclophosphamide (Tc) In Early Stage Hormone Positive Breast Cancer

e12576Background: TC is a regimen commonly used in early stage breast cancer. However, no specific recommendations exist in literature, regarding the number of cycles that can be used. i.e. TC4 vs TC6. Our aim, was to determine if TC4 is non-inferior to TC6 when used in the setting of early stage hormone positive breast cancer. Methods: We retrospectively reviewed 321 patients who were diagnosed with early stage hormone positive breast cancer between 2008 to 2015, at our institution who had Oncotype DX on file. Of these 70 patients were identified, who had received either TC4 or TC6. The number of cycles the patients received were based on provider preference. The two groups (TC4, TC6) were compared in regard to stage of cancer at diagnosis, node positivity, OncotypeDx score, grade of side-effects, compliance with adjuvant hormone therapy, recurrence and death-either from breast cancer or other causes. Median follow up was 4.5 years. Results: In the TC4 group(n = 53), 9(17%) had low oncotype( u003c 18), 39(73...